Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Free-Cash-Flow-To-The-Firm" stands at 14.05 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Amgen Inc's third quarter result of 4.85 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 91.51 percent compared to it's second quarter result.
Also, Amgen Inc's third quarter result of 4.85 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 21.35 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 14.05 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 6.46 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 54.06 percent compared to the value the year prior.
The 1 year change in percent is 54.06.
The 3 year change in percent is 38.28.
The 5 year change in percent is 26.55.
The 10 year change in percent is 45.50.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Free Cash Flow To The Firm | 905,699,262,464.00 |
![]() | Johnson & Johnson - Free Cash Flow To The Firm | 486,508,953,600.00 |
![]() | AbbVie Inc - Free Cash Flow To The Firm | 399,570,305,024.00 |
![]() | Roche Holding AG - Free Cash Flow To The Firm | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Free Cash Flow To The Firm | 280,205,508,085.11 |